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Abstract
Background: Ampullary adenocarcinoma is a rare gastrointestinal cancer associated with diverse outcomes due to
clinical and pathological heterogeneity. Standardized methods to better prognosticate and inform therapeutic
selection for ampullary adenocarcinoma are needed. This study explored the novel use and potential prognostic
utility of a 92-gene cancer classifier in ampullary adenocarcinomas.
Methods: In this prospectively-defined, blinded study of ampullary adenocarcinoma [N =54; stage T3 or higher
(57 %); Grade III (44 %); Node positive (55 %)], the performance of a 92-gene classifier was examined to predict the
ampullary subtype that was derived from histomorphological examination of resected ampullary samples. Outcome
data for relapse-free survival (RFS) and overall survival (OS) were plotted to compare the prognostic utility of
histological subtyping, histomolecular phenotyping, and the 92-gene classifier. Multivariate analysis was used to
determine clinicopathological variables that were independently associated with overall survival.
Results: The 92-gene classifier demonstrated sensitivities and specificities of 85 % [95 % CI, 66–94] and 68 %
[95 % CI, 48–84] and 64 % [95 % CI, 46–79] and 88 % [95 % CI, 70–98] for the pancreaticobiliary and intestinal
histological subtypes, respectively. For the 92-gene classifier, improved outcomes were observed for the intestine
versus the pancreaticobiliary prediction (median OS 108.1 v 36.4 months; HR, 2.17; 95 % CI, 0.98 to 4.79; P = 0.05).
Similar results were seen for ampullary adenocarcinoma stratification by histological subtype (P = 0.04) and
histomolecular phenotype (P = 0.02). Within poorly differentiated ampullary adenocarcinomas only the 92-gene
classifier demonstrated statistically significant differences in RFS and OS (P < 0.05).
Conclusions: Prognostic stratification of ampullary adenocarcinoma was similar for the 92-gene classifier,
histological subtype, and histomolecular phenotype. The 92-gene classifier provides an unbiased standardized
molecular-based approach to stratify ampullary tumors.
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Background
Adenocarcinomas of the ampulla of Vater are uncommon
gastrointestinal cancers with heterogeneous outcomes.
Histological classification of ampullary adenocarcinomas,
and subsequent clinical management, is challenging due
to the anatomical complexity and convergence of three
distinct epithelial types in this region [1]. While previous
studies suggest a role for histological classification of am-
pullary carcinoma into intestinal and pancreaticobiliary
subtypes through examination of morphological features,
the variability in subtype frequencies observed across
studies has contributed to the unclear prognostic utility of
histological examination alone [2–4]. Moreover, inter-
pathologist concordance for subtyping ampullary adeno-
carcinomas is reportedly poor, with k value of 0.57 for
intestinal and pancreaticobiliary subtypes, and a k value of
0.09 for the mixed subtype [5].
In addition to histological examination of morphological
features, immunohistochemical (IHC) stains have been
utilized to substantiate the intestinal versus pancreatico-
biliary morphology of these adenocarcinomas including
CK7, CK17, CK20 and CDX-2, and MUC1/2 [6]. Recently,
Chang et al. described clinically relevant histomolecular
phenotypes using both histomorphology and differential
protein expression of CDX2 and MUC1 in patients with
resected ampullary cancers [3]. While the histomolecular
phenotype represents progress in classifying ampullary
adenocarcinomas, IHC has challenges including tissue
heterogeneity and antigenicity, interpretation of staining
patterns, and inter/intra- observer variability [5, 7, 8].
Given the inherent subjective nature of both morpho-
logical evaluation and IHC, there exists a need for stan-
dardized approaches for tumor classification.
Genomic classifiers based on gene expression profiling of
known reference tumor types have reported performance
accuracies in the range of 80–90 % [9–13]. The 92-gene
assay (CancerTYPE ID® Biotheranostics, Inc.) is a clinically
validated cancer classifier that measures and interrogates
the collective expression of 92 genes to determine tumor
type and subtype utilizing a computational algorithm
trained on a reference database of more than 2000 tumors
[8, 13]. The objectives of the current study were to 1) evalu-
ate the performance of the 92-gene classifier to subtype
ampullary adenocarcinomas into intestine and pancreatico-
biliary types, and 2) compare the prognostic utility of histo-
logical examination (morphology alone), histomolecular
phenotype (morphology plus IHC) and the 92-gene classi-
fier (genomic classification) to stratify ampullary adenocar-
cinomas into intestinal and pancreaticobiliary subtypes.
Methods
Study population and pathologic examination
Clinicopathological and outcome data for 79 patients
with a diagnosis of ampullary adenocarcinoma who
underwent a pancreaticoduodenectomy at the University
of Texas, MD Anderson Cancer Center (UTMDACC)
were included. The ampullary tumor site of origin was
diagnosed based upon the original pancreaticoduode-
nectomy pathology report. Cases in which the ampullary
tumor site of origin could not be ascertained were not
included. Histological diagnosis (intestinal, pancreatico-
biliary, or mixed) and pathological features for each case
were reviewed by a specialist gastrointestinal pathologist
who was blinded from clinical outcomes. Tumors were
classified as intestinal (Int), pancreaticobiliary (Pb), or
mixed [4]. Cases with mixed histology, containing more
than 10 % of both histologic subtypes, were reclassified
based upon the predominant histological subtype as ei-
ther intestinal or pancreaticobiliary. Tumor staging was
per the AJCC 7th edition. Study approval was obtained
from the Institutional Review Board at UTMDACC.
Immunohistochemical scoring and histomolecular
phenotype
Tissue microarrays were constructed as described previ-
ously [14] from formalin-fixed paraffin embedded (FFPE)
material and consisted of three cores of tumor, and two
cores of paired normal small bowel mucosa when avail-
able. Immunohistochemical staining was scored based
on methods described by Chang et al. to maintain uni-
formity for comparisons [3]. For CDX2 (Biogenex, San
Ramon, CA, USA; clone CDX-88), both the intensity
and the percentage of positive cells were determined.
Tumors with a modified H score > 35 were considered
positive for CDX2 expression; MUC1 (Novocastra,
Newcastle, UK; clone Ma695) positivity was defined as
any positive staining [3]. Expression of CDX2 and
MUC1 was combined with the histological subtype to
classify ampullary adenocarcinomas into two different
histomolecular phenotypes, pancreaticobiliary (Pb) and
non-pancreaticobiliary (Non-Pb) as described [3]. Posi-
tive CK7 (Dako, Carpinteria, CA, USA; clone OVT-TL
12/30) and CK20 (Dako, Carpinteria, CA, USA; clone
KS20.8) expression was defined as >10 % of tumor cells
showing immunoreactivity.
92-gene classifier
For molecular profiling, 1 H&E and 3 unstained slides of
FFPE tumor sections were submitted for each case in a
blinded manner. Tumor cells were enriched by either
macro-dissection H&E or laser microdissection. The 92-
gene classifier (real-time RT-PCR) was performed on
total RNA as previously described, and used a pre-
specified computational algorithm that applies linear dis-
criminant analysis to generate probabilities for candidate
tumor types based on the degree of similarity of the
queried sample to the reference tumor database [15].
Cases exceeding the PCR analytical cut-off for internal
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controls (PCR cycling threshold >30) were considered
quality control (QC) failures. Cases were unblinded after
testing was completed. The main cancer type prediction
reported as the highest relative probability was utilized
to evaluate assay performance.
Statistical and survival analyses
Performance of the 92-gene classifier was evaluated based
on concordance with the ampullary subtype established by
histological (morphology alone) examination as the refer-
ence standard. Overall sensitivity (i.e. performance) was
calculated as the number of cases with a main cancer type
prediction that matched the reference histological subtype
divided by the total number of cases classifiable by the
assay. Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) for each sub-
type were calculated as previously described [15]. For the
92-gene classifier, ROC curve and AUC analysis was per-
formed using the rank order probability percentage of the
main type cancer prediction.
Survival curves were generated using the Kaplan-
Meier method. Survival differences were determined
with the log-rank test. P values < 0.05 were considered
statistically significant. Univariate Cox proportional haz-
ards regression models were used for relapse-free sur-
vival (RFS) and overall survival (OS). Clinicopathological
features with a P value < 0.05 were entered into multi-
variate Cox proportional hazard models for OS.
3-gene prognostic model
Cox regression models for OS and RFS was performed
on each of the 87 informative genes separately to iden-
tify genes with a significant (p-value < 0.05) effect on
outcome, either OS or RFS. For the 3-gene prognostic
model, Cox regression analysis was performed using the
expression levels of the three genes to calculate a linear
combination of gene expression score for each sample.
A linear combination score less than 0.45 was defined as
improved prognosis, whereas a linear combination score
greater than 0.45 was defined as poor prognosis [16].
Survival curves based on a cutpoint of 0.45 for the linear
combination of gene expression were generated using
the Kaplan-Meier method. Survival differences were de-




Of 79 ampullary adenocarcinoma cases, 25 samples
(32 %) did not pass quality control parameters; in a ma-
jority of these cases (N = 18), RNA quality was poor with
attrition rates consistent with FFPE block ages > 10 years.
Fifty-four tumor specimens were available to evaluate
the performance of the 92-gene classifier to subtype
ampullary adenocarcinomas (Fig. 1); an “off-panel”
tumor type for which the classifier was initially un-
trained [15]. Patient demographic and clinicopathologi-
cal features of the ampullary cohort are listed in Table 1.
Clinicopathological features of the cohort associated
with advanced disease include stage T2 disease or higher
(88.7 %), high grade (44.4 %, Grade III alone) and re-
gional lymph node metastasis (55.6 %). Histological
(morphology alone) evaluation of the ampullary cohort
characterized 20 tumors of intestinal subtype, 20 tumors
of pancreaticobiliary subtype and 14 tumors of mixed
histology. When only the predominant histology was
considered, cases were classified as 28 intestinal and 26
pancreaticobiliary tumors (Table 1).
Performance of the 92-gene cancer classifier
The output from the 92-gene cancer classifier is a main
cancer type prediction based on a comparison of the col-
lective expression of 92-genes in the tumor sample with
a database of reference tumors representing 28 main
cancer types and over 50 cancer subtypes. Within this
cohort, the main cancer type predictions by the 92-gene
classifier were Pancreaticobiliary (N = 31; 57.4 %), Intes-
tine (N = 21; 38.9 %), Gastroesophageal adenocarcinoma
(N = 1; 1.9 %), and Lung adenocarcinoma (N = 1; 1.9 %)
(Table 2). In addition to the main cancer type prediction,
the 92-gene assay distinguishes between different sub-
types of the main cancer type prediction as previously
described [15]. Of the 21 ampullary adenocarcinomas
classified by the 92-gene assay as intestinal, 14/21 (67 %)
were subtyped as colorectal adenocarcinoma and 7/21
(33 %) were subtyped as small intestine adenocarcinoma.
Of the 31 ampullary adenocarcinomas classified as pan-
creaticobiliary, 26/31 (84 %) were subtyped as gallblad-
der adenocarcinoma, 4/31 (13 %) were subtyped as
cholangiocarcinoma, and 1/31 (3 %) were subtyped as
pancreatic adenocarcinoma.
The overall performance of the 92-gene classifier for
ampullary subtyping, based on concordance of the main
cancer type prediction with the histological subtype, was
74 % [95 % CI, 61–84]. For the pancreaticobiliary histo-
logical subtype, the sensitivity and specificity of the 92-
gene classifier were 85 % [95 % CI, 66–94] and 68 %
[95 % CI, 48–84], respectively. For the intestinal histo-
logical subtype, the sensitivity and specificity of the 92-
gene classifier were 64 % [95 % CI, 46–79] and 88 %
[95 % CI, 70–98], respectively (Table 2).
Histomolecular phenotyping
The histomolecular (morphology plus IHC) pancreaticobili-
ary phenotype comprises ampullary adenocarcinomas that
are of pancreaticobiliary histology with negative CDX2 and
positive MUC1 expression by IHC. In contrast, the histomo-
lecular non-pancreaticobiliary phenotype includes ampullary
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adenocarcinomas that do not exhibit these specific features
[3]. Applying this histomolecular criteria results in 14 cases
that were classified as pancreaticobiliary phenotype (26 %),
and 40 cases that were classified as non-pancreaticobiliary
phenotype (74 %) (Table 1 and Table 3). Table 3 shows the
comparative data on CDX2 and MUC1 immunostaining
across the three classification approaches.
Comparative prognostic performance
Clinicopathological variables associated with improved OS
based on univariate analysis included absence of lymph
node metastasis [median OS 113.8 vs 41.8 m, P = 0.0343]
and negative margins (108.1 vs 18.8 m, P = 0.006). Individ-
ual immunohistochemical markers were not associated
with improved overall survival (Table 1). Figure 2 shows
the Kaplan–Meier curves comparing the ability of the
three ampullary subtyping methods (histology (morph-
ology alone), histomolecular (morphology plus IHC), and
92-gene classifier) to stratify patients for overall survival
and relapse-free survival. The intestinal histological
subtype was associated with improved OS compared
with the pancreaticobiliary histological subtype (108.1
v 34.6 months; P = 0.0348) (Fig. 2a). Histological sub-
typing did not significantly stratify the cohort for
Fig. 1 Case selection and flow diagram for molecular testing of ampullary adenocarcinoma. Seventy-nine cases of ampullary adenocarcinoma were
identified for this study. Tumor specimens were assigned a reference histological subtype (intestinal or pancreaticobiliary) by a gastrointestinal
pathologist. The comparator cohort comprised 54 cases to measure the prognostic performance of the 3 classifiers: 92-gene classifier, histological
subtype, and histomolecular phenotype
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relapse-free survival (RFS) (P = 0.12). Histomolecular
phenotype, which combines morphological features
with CDX2 and MUC1 immunostaining, demon-
strated improved OS (median OS 113.8 v 28.0 months;
P = 0.0174) and RFS (P = 0.0162) for the non-
pancreaticobiliary phenotype compared to the pan-
creaticobiliary phenotype (Fig. 2b). For the 92-gene
classifier, the difference in OS for the intestine versus pan-
creaticobiliary main cancer type predictions bordered on
significance (median OS 108.1 v 36.4 months; P = 0.05) and
RFS (P = 0.024) (Table 1 and Fig. 2c). After adjusting for
nodal and margin status, the three ampullary classifiers did
not demonstrate a significant difference in survival for the
pancreaticobiliary versus intestinal (or non-pancreaticobil-
iary) subtype (Additional file 1: Table S1). No statistically
significant difference in the prognostic performance was
observed across the 3 classifiers (data not shown).
As poor differentiation poses challenges for classification
methods that rely on morphological features, we compared
the prognostic utility of histological, histomolecular, and
the 92-gene classifier in a small subset of high grade or
poorly differentiated ampullary tumors (N = 24). In this
subset the 92-gene classifier demonstrated improved prog-
nosis for intestine compared to pancreaticobiliary main
Table 1 Clinicopathologic features of ampullary adenocarcinomas




Male 35 64.8 103.8






T1 6 11.3 NA
T2 17 32.1 103.8
T3 21 39.6 39.7
T4 9 17.0 108.1
N stage 0.034
N0 24 44.4 113.8
N1 30 55.6 41.8
Grade 0.92
I 2 3.7 113.8
II 28 51.9 63.7
III 24 44.4 108.1
Mucinous 0.17
Negative 50 92.6 108.1
Positive + signet ring 4 7.4 45.6
Perineural invasion 0.70
Negative 44 81.5 108.1
Positive 10 18.5 94.8
Lymphovascular invasion 0.46
Negative 38 70.4 113.8
Positive 16 29.6 57.2
Perioperative treatment 0.94
Neoadjuvant +/or adjuvant 25 46.3 145.9
None 29 53.7 103.8
Adenoma precursor lesion 0.56
Absent 33 61.1 113.8
Present 21 38.9 63.7
Resection margin 0.006
R0 52 96.3 108.1
R1 2 3.7 18.8
CK7 expression 0.70
Negative 12 22.2 63.7
Positive 42 77.8 108.1
CK20 expression 0.97
Negative 34 63.0 113.8
Table 1 Clinicopathologic features of ampullary adenocarcinomas
(Continued)
Positive 20 37.0 103.8
CDX2 expressionb 0.93
Negative 33 61.1 108.1
Positive 21 38.9 103.8
MUC1 expressionc 0.28
Negative 19 35.2 113.8
Positive 35 64.8 63.72
Histopathologic subtyped 0.035




(plus 6 mixed histology)
26 48.0 34.6
Histomolecular phenotype 0.017
Non-Pancreaticobiliary 40 74.1 113.8
Pancreaticobiliary 14 25.9 28.0
92-gene Classifiere 0.050
Intestinal 21 38.9 108.1
Pancreaticobiliary 31 57.4 36.4
Abbreviations: OS, overall survival
aT stage, N = 53, one case was carcinoma in situ
bPositive CDX2 expression was defined as modified H score > 35
cPositive MUC1 expression was defined as any positive staining
dP value for the predominant subtype. The predominant subtypes for the 14
samples with mixed histology are also indicated
eSingle gastroesophageal and single lung adenocarcinoma predictions
excluded. P < 0.05 was considered statistically significant
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cancer type prediction (OS, P = 0.045; RFS P = 0.014),
whereas no significance was seen with histological based
subtyping (OS, P = 0.27; RFS P = 0.78), or histomolecular
phenotype (OS, P = 0.31; RFS P = 0.14).
Exploratory analysis of gene subsets associated with
survival
The outcomes data associated with this cohort of ampul-
lary tumors allow for exploratory analysis of genes
whose expression is associated with overall survival, ra-
ther than histological subtype. Cox analysis using the
gene expression data from the 92-gene classifier identi-
fied three genes, IRX3, PYCR1, and TMPRSS3, that
showed a significant association (p-value less than 0.05)
with overall survival (OS) and relapse-free survival (RFS)
(Fig. 3a). The linear combination of gene expression
levels from IRX3, PYCR1, and TMPRS33 was used to
predict RFS and OS in the 54 patient cohort. As shown
in Fig. 3, a 3-gene expression score < 0.45 was associated
with improved OS (median OS 74.0 v 32.6 months; HR,
3.42; 95 % CI, 1.55 to 7.56; P = 0.0012) and improved
RFS (P = 0.0019, Fig. 3c). The OS survival group with
improved prognosis based on the 3-gene model is com-
prised mostly of tumors with an intestinal histological
subtype (70 %), whereas samples contained within the
poor survival group are mostly of the pancreaticobiliary
histological subtype (67 %) (Additional file 2: Table S2).
The 3-gene linear combination model had an AUC of
0.78 (95 % CI, 0.66 to 0.91) that is similar to the AUC =
0.76 (95 % CI, 0.63 to 0.89) for the 92-gene classifier
(Additional file 3: Figure S1).
Discussion
Identification of patient subgroups based on clinicopath-
ological and molecular characteristics is a validated ap-
proach for both tumor subclassification [17] and for the
optimal use of targeted therapies [18–23]. The ability to
stratify patients into different prognostic and/or treat-
ment groups is particularly important in cancers associ-
ated with a diverse range of outcomes such as ampullary
adenocarcinomas, which have classically been separated
into intestinal or pancreaticobiliary subtypes based on
histomorphological assessment [3, 4, 24, 25]. In this
blinded study, we demonstrate that a 92-gene cancer
classifier showed favorable performance in the classifica-
tion of ampullary adenocarcinomas into intestinal and
pancreaticobiliary histological subtypes, and that these
subtypes are prognostically distinct with discrete survival
outcomes. The 92-gene cancer classifier represents a
non-subjective classification method that demonstrated
comparative prognostic performance to histological sub-
typing (morphology alone) and histomolecular pheno-
typing (morphology plus IHC).
Demonstration that the 92-gene assay classified am-
pullary tumors into two statistically significant prog-
nostic groups is a novel finding of this study. Although
this work did not demonstrate a single method to have
significantly improved ability to prognostically stratify
ampullary adenocarcinoma, the comparable prognostic
utility of the 92-gene classier with histological subtyp-
ing and histomolecular phenotyping suggests that the
prognostic capability is partly consistent with histological
subtyping. Intriguingly the 92-gene classifier demonstrated
an improved ability to identify prognostic subgroups within
Table 2 Performance characteristics of the 92-gene classifier for the identification of histological subtypes in ampullary
adenocarcinomas
Histopathologic category N Type of prediction (N) Correct predictions Sensitivity (95 % CI) Specificity (95 % CI) PPV NPV
Ampullary-Intestinal 28 Intestine (18) 18 0.64 (0.46, 0.79) 0.88 (0.70, 0.98) 0.86 0.70
Pancreaticobiliary (9)
Gastroesophageal (1)
Ampullary-Pancreaticobiliary 26 Pancreaticobiliary (22) 22 0.85 (0.66, 0.94) .68 (0.48, 0.84) 0.71 0.83
Intestine (3)
Lung adenocarcinoma (1)
Total 54 40 0.74 (0.61, 0.84)
Abbreviations: N number of cases; 95 % CI 95 % confidence interval, PPV positive predictive value, NPV negative predictive value
Table 3 Differential expression of CDX2 and MUC1 in ampullary
adenocarcinomas
Histology Histomolecular 92-gene classifier
Int Pb Non-Pb Pb Int Pb
CDX2+/MUC1- 9 5 14 0 11 3
CDX2-/MUC1+ 10 18 14 14 4a 23
CDX2+/MUC1+ 6 1 7 0 4b 2
CDX2-/MUC1- 3 2 5 0 2 3
Total 28 26 40 14 21 31
Abbreviations: Int intestinal, Pb pancreaticobiliary,
Non-Pb non-pancreaticobiliary
aDoes not include the single lung adenocarcinoma prediction
bDoes not include the single gastroesophageal adenocarcinoma prediction
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poorly differentiated ampullary adenocarcinomas, though
the sample size for this analysis was small.
Currently, the classification of ampullary adenocarcin-
omas is performed by non-standardized examination of
tumor histomorphology. However, given the subjective
nature of histological classification it remains uncertain
which methodological approach to ampullary stratifica-
tion best reflects biology. This variation is highlighted by
the substantial differences in histological subtype desig-
nations that were observed amongst the three classifica-
tion methods. Whereas histology alone designated 48 %
of the cohort as pancreaticobiliary, histomolecular phe-
notyping designated 26 % and the 92-gene classifier des-
ignated 36 % of the cohort as pancreaticobiliary. Though
histomolecular phenotyping also considers differential
protein marker expression, this method fundamentally
relies upon histomorphological examination. In addition,
the challenges of immunohistochemical staining inter-
pretation and the establishment of optimal cut-points
for both CDX2 and MUC1 immune reactivity are limita-
tions for the application of histomolecular phenotyping




Fig. 2 Survival analysis of ampullary adenocarcinoma subtypes stratified by different methods. Kaplan-Meier curves for relapse-free survival and
overall survival as a function of (a) histological subtype, (b) histomolecular phenotype, and (c) 92-gene classifier. The solid line represents the in-
testinal (Int) or non-pancreaticobiliary (Non-Pb) subtypes. The dashed line represents the pancreaticobiliary subtype. For the 92-gene classifier, the
single gastroesophageal and single lung adenocarcinoma predictions were excluded
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64 % (0.46–0.79) and 85 % (0.66–0.94), and specificities
of 88 % (0.70–0.98) and 68 % (0.48–0.84) for the intes-
tinal and pancreaticobiliary histological subtypes, re-
spectively. The differential sensitivities and specificities
for the 92-gene assay reflect the increased number of
false positive pancreaticobiliary predictions (N = 9)
within the ampullary-intestine histological subtype in
contrast to the false positive intestine predictions (N = 3)
within the ampullary-pancreaticobiliary histological sub-
type. Unlike the setting in which the primary cancer site
is used as the clinical truth, the use of morphological
subtype as the gold-standard reference may be limited
by subjective determination.
The performance of the 92-gene classifier is promis-
ing for this off-panel tumor, particularly given that the
reference training database did not include ampullary
adenocarcinoma cases. The observed performance of
the 92-gene classifier to subtype these ampullary tu-
mors can be attributed to the discovery methodology of
the classifier, which included a data-dependent search
for gene combinations from whole genome expression
profiling and a genetic algorithm that allowed the gene
panel to evolve as a combination [27]. While reduced
performance in off-panel tumor types such as ampul-
lary adenocarcinoma is a potential limitation of gene
expression based classifiers, these findings support the
inherent scalability of the 92-gene assay to recognize a
diverse range of tumor types. These data are generally
consistent with the utilization of a dichotomous sub-
classification for ampullary adenocarcinomas. This
finding is in agreement with a previous microarray ana-
lysis [25] and provides information on cellular context,
which points to distinct epithelial origins of ampullary
tumors with different outcomes.
Limitations of this study are that, in contrast to the re-
cent histomolecular phenotyping by Chang et al. [3], this
current study involves a smaller cohort of patients, likely
contributing to the lack of significance for the 3
C
Fig. 3 Survival analysis of ampullary adenocarcinoma stratified by the 3-gene model. a Location and function of the 3-genes with a significant
(p < 0.05) association with overall survival. Kaplan-Meier curves for relapse-free (b) and overall survival (c). The solid line represents tumors with a
collective gene expression score less than 0.45 that represent the ampullary subset with better OS. The dashed line represents tumors with a
collective gene expression score greater than 0.45 that represent the ampullary subset with worse OS
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classifiers in multivariate analysis (Additional file 1:
Table S1). Additional limitations of this study were its
retrospective nature and use of both untreated and
neoadjuvantly treated primary tumors. Further validation
of these findings in a larger dataset is needed.
Based on the ability of the 92-gene classifier to meas-
ure gene expression in biologically-relevant pathways
such as lineage commitment and signal transduction,
an exploratory analysis was performed using the cases
from this study as a training set to identify a 3-gene ex-
pression model that stratified this ampullary cohort
into two statistically significant survival groups (HR =
3.42, P = 0.0012). Although a majority of cases in the
poor survival group had a pancreaticobiliary histo-
logical subtype, a significant portion (33 %) of cases in
this group had an intestinal histological subtype. Simi-
larly, 30 % of the cases in the improved survival group
had a pancreaticobiliary histological subtype, whereas
the majority was intestinal (Additional file 2: Table S2).
This 3-gene expression model suggests that the collect-
ive expression of IRX3, PYCR1, and TMPRSS3 reflects
the additional biological importance of tumor invasion, in-
testinal differentiation, and cellular metabolism [28–34],
in the prognosis of ampullary cancers. The increased ex-
pression of IRX3 and TMPRSS3 in the poor prognosis
ampullary subset is consistent with the biological func-
tions of these genes in promoting tumorigenesis and
tumor invasion, respectively [29, 32]. The exploratory 3-
gene signature represents a hypothesis-generating findings
and further validation is needed.
At the present time the main clinical utility from
stratifying ampullary adenocarcinomas results from im-
proved prognostication. The clinical impact of classifying
ampullary tumors to inform therapeutic decisions in the
adjuvant or metastatic settings has not been proven.
Histological subtyping of some ampullary cases in the
European Study Group for Pancreatic Cancer (ESPAC)-3
prospective trial demonstrated improved DFS (P = 0.01),
but not OS (P = 0.28). However, due to small number of
cases with known histological subtype the outcomes
stratified by chemotherapy type and histological subtype
were not analyzed [35, 36]. Based upon the reproducible
identification of not only distinct prognostic but also
biologically unique ampullary subgroups, a clinical trial
utilizing subtype guided therapy [e.g. fluoropyrimidine/
oxalipliatin for the intestinal ampullary subtype and
gemcitabine/cisplatin for pancreaticobiliary ampullary
subtype has merit. Additionally, the role of novel ap-
proved agents and biomarkers with therapeutic intent
needs to be explored in ampullary cancers (e.g. her-2
and RAS for intestinal subtype and IDH1, ARID-1,
FGFR for biliary subtypes). One can envision that pro-
gress made in pancreas, intestinal and cholangiocarcino-
mas may directly impact subtypes of ampullary cancers.
Conclusion
In conclusion, the results of this study demonstrate that
the 92-gene assay offers a standardized and reproducible
approach beyond the review of morphology and immu-
nohistochemistry to classify ampullary cancers [5, 8].
The 92-gene assay may potentially provide an improved
method to classify the molecular subtype of unresectable
periampullary cancers in which primary resection tissue
is not present and thus the anatomic source of the can-
cer (pancreatic vs. biliary vs. duodenal vs. ampullary)
cannot be determined. A potential next step in the clin-
ical utility of the 92-gene assay is to integrate its use into
the broader diagnostic armamentarium of periampullary
cancers and allow the molecular subtype designation to
guide tailored therapy.
Additional files
Additional file 1: Table S1. Multivariate analysis of clinicopathological
features and the three ampullary subtyping methods. Abbreviations: HR,
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